GSK shingles vaccine performs
April 29, 2015Research and Development, Sales and Marketing GSK, GlaxoSmithKline, HZ/su, Merck, zostovax
GlaxoSmithKline’s HZ/su vaccine candidate for the prevention of shingles has demonstrated promising benefits across all age groups in a late-stage …
Conference round-up: companies go big on hepatitis C at EASL
April 29, 2015Sales and Marketing Bristol-Myers Squibb, EASL, Merck, daclatasvir, daklinza
Big pharma names posted favourable results for hepatitis C treatments as they jostled for position as market leaders at the …
RSA hires two consultants in Germany
April 29, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andreas Reimer, Ji Kwon, rsa
Executive search and interims firm RSA has appointed two consultants to its teams in the DACH region. Andreas Reimer (pictured) …
Helping Nepal – SHL to Match Staff Donations
April 29, 2015Sales and Marketing helping nepal, shl group, world vision
In immediate response to the devastating earthquake that left Nepal in ruins on April 25th, SHL quickly reached out to …
BMS lifted by new products
April 28, 2015Sales and Marketing BMS, NICE, Q1, eams, immuno-oncology and hepatitis C
New drugs have helped Bristol-Myers Squibb see a slight increase in sales for the first quarter of 2015. Total revenues …
Celgene splashes out on cancer R&D firm
April 28, 2015Research and Development, Sales and Marketing
Oncology specialists Celgene have made a $485 million outlay to buy Quanticel Pharmaceuticals, to increase its effort and investment in …
UK ‘has ten years to become global biotech leader’
April 28, 2015Manufacturing and Production, Research and Development, Sales and Marketing
The UK should be home to ‘the third global cluster’ for biotech in the next 10 years, according to a …
M&A drama continues as Mylan rejects Teva
April 28, 2015Sales and Marketing M&A, MA, Mylan, Perrigo, Teva, bids, generics, takeovers
Mylan has firmly rejected Teva’s acquisition bid, even though its own bid for Irish firm Perrigo has also been turned …
Researchers hit out at ‘alarming’ increase in MS drug costs
April 27, 2015Manufacturing and Production, Research and Development, Sales and Marketing
Researchers have hit out at the ‘alarming’ rise in the costs of disease-modifying treatments for multiple sclerosis, in a new …
Big-name generics among new CHMP recommendations
April 27, 2015Sales and Marketing CHMP, EMA, European Medicines Agency, Lyrica, pregabalin
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended 11 new medicines for approval, among them several …
The Pharmafocus debate: Is the price of new hepatitis C treatments fair?
April 27, 2015Research and Development, Sales and Marketing Doctors of the World, Drug pricing, EFPIA, Gilead, MSF, drug cost, hepatitis C, patents, sofosbuvir, sovaldi
YES – says Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), who argues that …
EMA approves BMS’ Opdivo for advanced skin cancer
April 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer
Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …
AstraZeneca looks to oncology match-ups to boost sales
April 24, 2015Sales and Marketing AstraZeneca, Brilinta, Celgene, Innate, Juno, farxiga, ticagrelor
AstraZeneca posted a 1% increase in revenue in its first-quarter 2015 financials – and is investing the money to back …
Clinigen buys Idis for £225 million
April 24, 2015Sales and Marketing CBPE Capital, Clinigen, IDIS, unlicensed
UK speciality pharma group Clinigen is paying £225 million to acquire the Surrey-based unlicensed supplier of medicines firm Idis. Unlicensed …
Actavis confirms retirement of its comms officer
April 24, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, charles mayr
Ireland-based pharma firm Actavis has announced its chief communications officer Charles Mayr (pictured) is to retire shortly due to health …
Novartis heart drug steps closer to EAMS scheme
April 23, 2015Sales and Marketing LCZ696, MHRA, Medicines and Healthcare products Regulatory Agency, NICE, eams, pim, sacubitril/valsartan
Novartis’ investigational heart failure drug LCZ696 has been handed a Promising Innovative Medicine designation (PIM) after showing that it significantly …
Novartis and Abbott start year with strong Q1 sales
April 23, 2015Sales and Marketing Abbott, Amgen, Cosentyx, GSK, Neupogen, Novartis, Secukinumab, Zarxio, biosimilar, filgrastim, financials
Novartis and Abbott have both posted strong first-quarter results and made bullish predictions about their financial performance in 2015. Novartis …
Novo Nordisk obesity drug is launched in the US
April 23, 2015Sales and Marketing Novo Nordisk, liraglutide, obesity, overweight, saxenda, world health organization
Novo Nordisk is rolling out its obesity drug Saxenda across the US for the treatment of obese adult patients. Saxanda …
Gilead presents new Sovaldi data
April 23, 2015Sales and Marketing GS-5816, GS-9857, Gilead, NS3/4A, SVR12, hepatitis C, sofosbuvir, sovaldi
Gilead is looking to several new studies to support future new Sovaldi combinations and broadened treatment groups for its hepatitis …
Boehringer assures future growth following sales drop
April 23, 2015Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results
Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
